Photo of Alessandra Longhi MD
Alessandra Longhi, MD
+39-051-6366411
+39-051-6366277
  1. Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Longhi A, Paioli A, Palmerini E, Cesari M, Abate ME, Setola E, Spinnato P, Donati D, Hompland I, Boye K. Acta Oncol. 2018 Sep 12:1-4. doi: 10.1080/0284186X.2018.1503714. [Epub ahead of print] No abstract available.
  2. Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, Gronchi A, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, D'Ambrosio L, Willegger M, Scoccianti G, Ferrari S. Eur J Cancer. 2017 Feb 3;74:9-16. doi: 10.1016/j.ejca.2016.12.016
  3. Ewing sarcoma in patients over 40 years of age: a prospective analysis of 31 patients treated at a single institution. Cesari M, Righi A, Cevolani L, Palmerini E, Vanel D, Donati DM, Cammelli S, Gambarotti M, Ferrari C, Paioli A, Longhi A, Abate ME, Picci P, Ferrari S. Tumori. 2016 Oct 13;102(5):481-487. doi: 10.5301/tj.5000534.
  4. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S, Grignani G, Tamburini A, Pollack SM, Picci P, Ferrari S. BMC Cancer. 2016 Apr 20;16:280
  5. Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. Frakulli R, Salvi F, Balestrini D, Parisi A, Palombarini M, Cammelli S, Rocca M, Salone M, Longhi A, Ferrari S, Morganti AG, Frezza G. Anticancer Res. 2015 Oct;35(10):5581-6.
  6. Salivary gland second cancer after bone sarcoma treatment. Longhi A, Errani C, Gambarotti M, Ferrari C, Kreshak J, Panagopoulos GN, Mavrogenis AF, Donati D. Eur J Orthop Surg Traumatol. 2015 Oct;25(7):1201-4.
  7. Lung cancer presenting as a metastasis to the tibial bones: a case report. Gurrieri L, Longhi A, Braghetti A. Tumori. 2015 Mar 20;101(1):e18-20.
  8. A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Longhi A, Reif M, Mariani E, Ferrari S., Evid Based Complement Alternat Med. 2014;2014:210198. doi: 10.1155/2014/210198. Epub 2014 Mar 31
  9. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C. Cancer. 2012 Oct 15;118(20):5050-9. doi: 10.1002/cncr.27493. Epub 2012 Mar 13.
  10. Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. Palmerini E, Gambarotti M, Staals EL, Zanella L, Sieberova G, Longhi A, Cesari M, Bonarelli S, Picci P, Ruggieri P, Alberghini M, Ferrari S.Clin Sarcoma Res. 2012 Jan 27;2(1):4.
  11. Phase II study of imatinib in advanced chordoma.Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG J Clin Oncol. 2012 Mar 20;30(9):914-20.
  12. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P.J Clin Oncol. 2012 Mar 10;30(8):850-6
  13. Aggressive fibromatosis of the neck treated with a combination of chemotherapy and indomethacin. Longhi A, Errani C, Battaglia M, Alberghini M, Ferrari S, Mercuri M, Molinari M.Ear Nose Throat J. 2011 Jun;90(6):E11-5. Review.
  14. Periosteal osteosarcoma: a single-institution experience.Cesari M, Alberghini M, Vanel D, Palmerini E, Staals EL, Longhi A, Abate M, Ferrari C, Balladelli A, Ferrari S. Cancer. 2011 Apr 15;117(8):1731-5.
  15. Palliative therapy for osteosarcoma. Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, Bacci G, Mercuri M. Expert Rev Anticancer Ther. 2011 Feb;11(2):217-27.
  16. High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature. Longhi A, Errani C, Magagnoli G, Alberghini M, Gambarotti M, Mercuri M, Ferrari S.J Chemother. 2010 Dec;22(6):413-8.
  17. Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. Abate ME, Longhi A, Galletti S, Ferrari S, Bacci G.Pediatr Blood Cancer. 2010 Oct;55(4):652-4
  18. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study. Ferrari S, Palmerini E, Alberghini M, Staals E, Mercuri M, Barbieri E, Longhi A, Cantero L, Cesari M, Abate M, Balladelli A, Picci P, Bacci G.Tumori. 2010 Mar-Apr;96(2):213-8.
  19. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M.Cancer Treat Rev. 2010 Feb;36(1):1-7
  20. Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy. Bacci G, Palmerini E, Staals EL, Longhi A, Barbieri E, Alberghini M, Ferrari S.Radiother Oncol. 2009 Nov;93(2):383-7
  21. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, Balladelli A, Pratelli L, Bacci G.J Chemother. 2009 Apr;21(2):205-10.
  22. Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution. Bacci G, Boriani S, Balladelli A, Barbieri E, Longhi A, Alberghini M, Scotlandi K, Forni C, Pollastri P, Vanel D, Mercuri M.Eur Spine J. 2009 Aug;18(8):1091-5.
  23. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N.Cancer Res. 2009 Mar 15;69(6):2443-52.
  24. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Avnet S, Longhi A, Salerno M, Halleen JM, Perut F, Granchi D, Ferrari S, Bertoni F, Giunti A, Baldini N.Int J Oncol. 2008 Dec;33(6):1231-8.
  25. Osteosarcoma in patients older than 65 years. Longhi A, Errani C, Gonzales-Arabio D, Ferrari C, Mercuri M.J Clin Oncol. 2008 Nov 20;26(33):5368-73.
  26. Spontaneous regression of lung metastasis from osteosarcoma: a case report. Bacci G, Palmerini E, Staals EL, Ferrari S, Battaglia M, Longhi A, Bertoni F, Briccoli A.J Pediatr Hematol Oncol. 2008 Jan;30(1):90-2.
  27. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Benassi MS, Briccoli A, Serra M, Picci P.Ann Oncol. 2007 Dec;18(12):2037-40. Epub 2007 Oct 24.
  28. Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours. Bacci G, Balladelli A, Forni C, Longhi A, Serra M, Fabbri N, Alberghini M, Ferrari S, Benassi MS, Picci P.J Bone Joint Surg Br. 2007 Sep;89(9):1229-33.
  29. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Longhi A, Ferrari S, Bacci G, Specchia S.Anticancer Drugs. 2007 Jul;18(6):737-44.
  30. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Bacci G, Ferrari S, Mercuri M, Longhi A, Fabbri N, Galletti S, Forni C, Balladelli A, Serra M, Picci P.Acta Orthop. 2007 Jun;78(3):377-84.
  31. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P.J Surg Oncol. 2007 Aug 1;96(2):118-23.
  32. Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma. Ferrari S, Bertoni F, Palmerini E, Errani C, Bacchini P, Pignotti E, Mercuri M, Longhi A, Cesari M, Picci P.J Pediatr Hematol Oncol. 2007 Jun;29(6):364-8.
  33. Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Bacchini P, Alberghini M, Fabbri N, Benassi M, Briccoli A, Picci P.Cancer. 2007 Feb 15;109(4):780-6.
  34. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. Bacci G, Longhi A, Forni C, Fabbri N, Briccoli A, Barbieri E, Mercuri M, Balladelli A, Ferrari S, Picci P.Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):505-11. Epub 2006 Nov 21.
  35. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. Bacci G, Longhi A, Bertoni F, Briccoli A, Versari M, Pignotti E, Picci P.Acta Orthop. 2006 Dec;77(6):938-43.
  36. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P.J Pediatr Hematol Oncol. 2006 Dec;28(12):774-80.
  37. Primary bone osteosarcoma in the pediatric age: state of the art. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G.Cancer Treat Rev. 2006 Oct;32(6):423-36. Epub 2006 Jul 24. Review.
  38. Late relapse in osteosarcoma. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Cesari M, Longhi A, Bacci G.J Pediatr Hematol Oncol. 2006 Jul;28(7):418-22.
  39. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F.Acta Oncol. 2006;45(4):469-75.
  40. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Bacci G, Longhi A, Cesari M, Versari M, Bertoni F.Cancer. 2006 Jun 15;106(12):2701-6.
  41. Pulmonary nodules in osteosarcoma patients: differential diagnosis of central venous catheter-related infections in the lungs.Longhi A, Rimondi E, Loro L, Tetta C, Rossi G, DeBenedittis M, Bacci G.Radiol Med. 2006 Mar;111(2):192-201. English, Italian.
  42. The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P.Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):766-72. Epub 2006 Apr 19.
  43. Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Bacci G, Longhi A, Ferrari S, Mercuri M, Barbieri E, Bertoni F, Bacchini P, Picci P.Eur J Surg Oncol. 2006 Nov;32(9):974-9. Epub 2006 Apr 18.
  44. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Bacci G, Loro L, Longhi A, Bertoni F, Bacchini P, Versari M, Picci P, Serra M.Anticancer Drugs. 2006 Apr;17(4):411-5.
  45. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P.Cancer. 2006 Mar 1;106(5):1154-61.
  46. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Eur J Cancer. 2005 Dec;41(18):2836-45. Epub 2005 Nov 17.
  47. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G; Italian and Scandinavian Sarcoma Groups.J Clin Oncol. 2005 Dec 1;23(34):8845-52. Epub 2005 Oct 24.
  48. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, Versari M, Picci P.Acta Oncol. 2005;44(7):748-55.
  49. Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Bacci G, Longhi A, Barbieri E, Ferrari S, Mercuri M, Briccoli A, Versari M, Pignotti E, Picci P.J Pediatr Hematol Oncol. 2005 Oct;27(10):517-20.
  50. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, Picci P.Eur J Cancer. 2005 Sep;41(14):2079-85.
  51. Height as a risk factor for osteosarcoma. Longhi A, Pasini A, Cicognani A, Baronio F, Pellacani A, Baldini N, Bacci G.J Pediatr Hematol Oncol. 2005 Jun;27(6):314-8.
  52. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. Bacci G, Longhi A, Bertoni F, Bacchini P, Ruggeri P, Versari M, Picci P.J Pediatr Hematol Oncol. 2005 Mar;27(3):129-34.
  53. Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors. Longhi A, Mercuri M, Bianchi G, Errani C, Bacci G.Obstet Gynecol. 2005 Feb;105(2):447; author reply 447-8. No abstract available
  54. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: a comparison of results obtained in single-institution and multicenter trials. Bacci G, Mercuri M, Longhi A, Setola E, Gozzi E, Forni C.Chir Organi Mov. 2004 Oct-Dec;89(4):283-92. English, Italian.
  55. Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy. Longhi A, Pasini E, Bertoni F, Pignotti E, Ferrari C, Bacci G.J Chemother. 2004 Dec;16(6):582-8.
  56. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, Versari M.Tumori. 2004 Sep-Oct;90(5):478-84.
  57. Simultaneous osteosarcoma lung metastasis and second primary lung cancer. Longhi A, Bertoni F, Bacchini P, Albisinni U, Mercati U, Bacci G.J Pediatr Hematol Oncol. 2004 Jul;26(7):457-61.
  58. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992.Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, Barbieri E, Pignotti E, Rosito P, Versari M.Eur J Cancer. 2004 Jan;40(1):73-83.
  59. Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Bacci G, Ferrari S, Longhi A, Donati D, Barbieri E, Forni C, Bertoni F, Manfrini M, Giacomini S, Bacchini P.Oncol Rep. 2004 Jan;11(1):111-20.
  60. Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing's sarcoma. Longhi A, Barbieri E, Fabbri N, Macchiagodena M, Favale L, Lippo C, Salducca N, Bacci G.Tumori. 2003 Sep-Oct;89(5):569-72.
  61. Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. Bacci G, Ferrari S, Longhi A, Forni C, Ruggieri P, Briccoli A, De Paolis M, Setola E.J Clin Oncol. 2003 Dec 15;21(24):4662-3. No abstract available.
  62. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. Bacci G, Forni C, Ferrari S, Longhi A, Bertoni F, Mercuri M, Donati D, Capanna R, Bernini G, Briccoli A, Setola E, Versari M.J Pediatr Hematol Oncol. 2003 Nov;25(11):845-53.
  63. A comment on "Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders". Bacci G, Longhi A, Forni C, Setola E, Ferrari ES.Eur J Cancer. 2003 Nov;39(17):2566; author reply 2567-8. No abstract available.
  64. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, Versari M, Setola E, Briccoli A, Barbieri E.Ann Oncol. 2003 Nov;14(11):1654-9.
  65. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Bacci G, Ferrari S, Longhi A, Donati D, Manfrini M, Giacomini S, Briccoli A, Forni C, Galletti S.Acta Orthop Scand. 2003 Aug;74(4):449-54.
  66. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, Manfrini M, Galletti S.Ann Oncol. 2003 Jul;14(7):1126-34.
  67. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Bacci G, Ferrari S, Longhi A, Forni C, Loro L, Beghelli C, Tremosini M, Versari M.Oncol Rep. 2003 Jul-Aug;10(4):851-7.
  68. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor.Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R, Bacchini P, Donati D, Manfrini M, Bernini G, Lari S.Cancer. 2003 Jun 15;97(12):3068-75.
  69. A comment and update on "Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival?". Bacci G, Ferrari S, Bertoni F, Longhi A, Bacchini P, Giacomini S, Forni C.Eur J Cancer. 2003 Mar;39(4):548-9. No abstract available.
  70. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. Longhi A, Macchiagodena M, Vitali G, Bacci G.J Pediatr Hematol Oncol. 2003 Apr;25(4):292-6.
  71. Local and systemic control in Ewing's sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/or surgery. Bacci G, Ferrari S, Longhi A, Versari M, Forni C, Donati D, Manfrini M, Trentani P, Barbieri E.J Bone Joint Surg Br. 2003 Jan;85(1):107-14.
  72. Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. Bacci G, Ferrari S, Mercuri M, Longhi A, Giacomini S, Forni C, Bertoni F, Manfrini M, Barbieri E, Lari S, Donati D.J Pediatr Hematol Oncol. 2003 Feb;25(2):118-24.
  73. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Longhi A, Pignotti E, Versari M, Asta S, Bacci G.Oncol Rep. 2003 Jan-Feb;10(1):151-5.
  74. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C; Italian Sarcoma Group/Scandinavian Sarcoma Group.J Chemother. 2002 Apr;14(2):198-206.
  75. Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Bacci G, Mercuri M, Longhi A, Bertoni F, Barbieri E, Donati D, Giacomini S, Bacchini P, Pignotti E, Forni C, Ferrari S.Eur J Cancer. 2002 Nov;38(17):2243-51.
  76. High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. Bacci G, Ferrari S, Longhi A, Forni C, Zavatta M, Versari M, Smith K.J Pediatr Hematol Oncol. 2002 Jan;24(1):27-30.
  77. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, Forni C, Bertoni F, Versari M, Pignotti E.J Bone Joint Surg Br. 2002 Jan;84(1):88-92. No abstract available.
  78. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M.Oncol Rep. 2002 Jan-Feb;9(1):171-5.
  79. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, Donati D, Lari S, Forni C, DePaolis M.Eur J Cancer. 2001 Nov;37(16):2030-9.
  80. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. Longhi A, Fabbri N, Donati D, Capanna R, Briccoli A, Biagini R, Bernini G, Ferrari S, Versari M, Bacci G.J Chemother. 2001 Jun;13(3):324-30.
  81. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G.Ann Oncol. 2001 Aug;12(8):1145-50.
  82. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Bacci G, Ferrari S, Longhi A, Forni C, Giacomini S, Lari S, Versari M. Oncol Rep. 2001 Jul-Aug;8(4):883-8.
  83. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases. Bacci G, Ferrari S, Ruggieri P, Biagini R, Fabbri N, Campanacci L, Bacchini P, Longhi A, Forni C, Bertoni F.Acta Orthop Scand. 2001 Apr;72(2):167-72.
  84. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A, Donati D, Forni C, Campanacci L, Campanacci M.Clin Orthop Relat Res. 2001 May;(386):186-96.
  85. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Bacci G, Ferrari S, Tienghi A, Bertoni F, Mercuri M, Longhi A, Fiorentini G, Forni C, Bacchini P, Rimondini S, De Giorgi U, Picci P.Eur J Surg Oncol. 2001 Feb;27(1):98-104.
  86. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. Bacci G, Ferrari S, Longhi A, Forni C, Bertoni F, Fabbri N, Zavatta M, Versari M.J Chemother. 2001 Feb;13(1):93-9.
  87. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, Salduca N, Versari M, Smith KV.Eur J Cancer. 2001 Jan;37(1):32-8.
  88. Osteosarcoma in blood relatives. Longhi A, Benassi MS, Molendini L, MacchiagodenaM,Picci P, Bacci G.Oncol Rep. 2001 Jan-Feb;8(1):131-6. Review
  89. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Bacci G, Ferrari S, Comandone A, Zanone A, Ruggieri P, Longhi A, Bertoni F, Forni C, Versari M, Rimondini S.Acta Oncol. 2000;39(1):111-6.
  90. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M.J Clin Oncol. 2000 Dec 15;18(24):4016-27.
  91. Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. Longhi A, Porcu E, Petracchi S, Versari M, Conticini L, Bacci G.Cancer. 2000 Nov 1;89(9):1961-5.
  92. Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Bacci G, Ruggieri P, Bertoni F, Ferrari S, Longhi A, Biagini R, Zavatta M, Versari M, Forni C. Oncol Rep. 2000 Sep-Oct;7(5):1129-33.
  93. Delay in diagnosis of high-grade osteosarcoma of the extremities. Has it any effect on the stage of disease? Bacci G, Ferrari S, Longhi A, Mellano D, Giacomini S, Forni C.Tumori. 2000 May-Jun;86(3):204-6.
  94. Brain tumors as second malignant neoplasms in patients with osteosarcoma treated with adjuvant and neoadjuvant chemotherapy: report of 2 cases. Longhi A, Gamberi G, Bacci G.J Chemother. 2000 Jun;12(3):261-2.
  95. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the Istituto Rizzoli. Bacci G, Ferrari S, Bertoni F, Donati D, Bacchini P, Longhi A, Brach Del Prever A, Forni C, Rimondini S.J Clin Oncol. 2000 Feb;18(4):885-92
  96. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Bacci G, Briccoli A, Ferrari S, Saeter G, Donati D, Longhi A, Manfrini M, Bertoni F, Rimondini S, Monti C, Forni C.Oncol Rep. 2000 Mar-Apr;7(2):339-46.
  97. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P.J Clin Oncol. 2000 Jan;18(1):4-11.
  98. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Ferrari S, Mercuri M, Picci P, Bertoni F, Brach del Prever A, Tienghi A, Mancini A, Longhi A, Rimondini S, Donati D, Manfrini M, Ruggieri P, Biagini R, Bacci G.Tumori. 1999 Nov-Dec;85(6):458-64.
  99. Prognostic significance of serum LDH in Ewing's sarcoma of bone. Bacci G, Ferrari S, Longhi A, Rimondini S, Versari M, Zanone A, Forni C.Oncol Rep. 1999 Jul-Aug;6(4):807-11.
  100. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. Bacci G, Picci P, Mercuri M, Ferrari S, Longhi A, Cesari M, Rosito P, Mancini AF, Barbieri E, Baldini N.Acta Oncol. 1998;37(7-8):671-6.
  101. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. Ferrari S, Mercuri M, Rosito P, Mancini A, Barbieri E, Longhi A, Rimondini S, Cesari M, Ruggieri P, Di Liddo M, Bacci G. J Chemother. 1998 Dec;10(6):484-91.
  102. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Bacci G, Ferrari S, Donati D, Longhi A, Bertoni F, Di Fiore M, Comandone A, Cesari M, Campanacci M.Oncol Rep. 1998 Sep-Oct;5(5):1259-63.
  103. Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. Bacci G, Ferrari S, Mercuri M, Longhi A, Capanna R, Tienghi A, Brach del Prever A, Comandone A, Cesari M, Bernini G, Picci Acta Oncol. 1998;37(1):41-8.
  104. Long-term follow-up for patients with Ewing's sarcoma of bone treated with adjuvant and neoadjuvant chemotherapy. Bacci G, Ferrari S, Barbieri E, Longhi A, Forni C, Cesari M, Sarti M, Gasbarrini A, Rosito P, Delprever A.Oncol Rep. 1997 Sep-Oct;4(5):977-85.
  105. Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. Vicario G, Celio L, Bajetta E, Zampino M, Longhi A, Buzzoni R, Botti C, Bogni A, Bombardieri E, Rimassa L, Laffranchi A.Oncol Rep. 1995 Jan;2(1):63-8.
  106. Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer. Bajetta E, Celio L, Zilembo N, Bono A, Galluzzo D, Zampino MG, Longhi A, Ferrari L, Buzzoni R.Tumori. 1994 Feb 28;80(1):28-32.
  107. Chemotherapy of advanced malignant-melanoma (review).Debraud F, Bajetta E, Zampino M, Nole F, Longhi A, Zilembo N, Colleoni M.Oncol Rep. 1994 Jan;1(1):83-8.
  108. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Martoni A, Longhi A, Canova N, Pannuti F.Oncology. 1991;48(1):1-6.
  109. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. Pannuti F, Longhi A, Martoni A, Piana E, Baroni M.Chemioterapia. 1987 Dec;6(6):396-8.
Utilizza SharethisShareThis  Scrivi una email  Vai a facebook  Vai a twitter